Navigation Links
ViroPharma to Present at the Cowen & Company 29th Annual Healthcare Conference
Date:3/11/2009

EXTON, Pa., March 11 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that Vincent Milano, president and chief executive officer of ViroPharma, will present at the Cowen & Company 29th Annual Healthcare Conference at 11:00 A.M. ET on Wednesday, March 18, 2009. The conference is being held at the Boston Marriott Copley Place.

ViroPharma's presentations will be webcast live for investors through www.viropharma.com and available for a period of 14 days following the conferences.

About ViroPharma Incorporated

ViroPharma Incorporated is a biopharmaceutical company dedicated to the development and commercialization of products that address serious diseases treated by physician specialists and in hospital settings. ViroPharma commercializes Vancocin(R) (vancomycin hydrochloride capsules, USP), approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains, and Cinryze(TM) (C1 inhibitor (human)) for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), also known as C1 inhibitor deficiency (for prescribing information on ViroPharma's commercial products, please download the package inserts at http://www.viropharma.com/Products.aspx). ViroPharma currently focuses its drug development activities in diseases including cytomegalovirus (CMV), HAE and C. difficile.

ViroPharma routinely posts information, including press releases, which may be important to investors in the investor relations and media sectio
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. ViroPharma to Host Investor Teach-In Educational Symposium on Hereditary Angioedema
2. ViroPharma to Release 2008 Fourth Quarter and Full Year Financial Results on February 24, 2009
3. ViroPharma Reports Results of Phase 3 Clinical Trial for Maribavir in Bone Marrow Transplant Patients
4. ViroPharma to Present at the 27th Annual J.P. Morgan Healthcare Conference
5. ViroPharma Provides Update on Vancocin(R)
6. ViroPharma Submits Supplemental Biologics License Application for Cinryze(TM) to Treat Acute Attacks of Hereditary Angioedema
7. ViroPharma To Present At The 20th Annual Piper Jaffray Healthcare Conference
8. ViroPharma to Discuss Commercialization and Launch of Cinryze(TM) on November 5, 2008
9. ViroPharma Incorporated Reports Third Quarter 2008 Financial Results
10. ViroPharma to Release 2008 Second Quarter Financial Results on July 30, 2008
11. ViroPharma Incorporated Reports First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... Robert LaPrade, MD, PhD, ... Steadman Philippon Research Institute, participated in the study “ ... Specialization? ” This was a collaborative project from the ... that was recently published in the American Journal of ... limited, there is evidence that early sport specialization may ...
(Date:6/2/2015)... IL (PRWEB) June 02, 2015 While ... action adaptions of comic books, comic books themselves are ... , Comics Uniting Nations plans to produce educational comics ... forthcoming Global Goals for Sustainable Development - an international ... extreme poverty, hunger, health, education, sustainable energy, inequality, climate ...
(Date:6/2/2015)... North Vancouver, B.C., Canada (PRWEB) June 02, 2015 ... American publisher of audit, compliance and risk ... of a new online risk management effectiveness gap-improvement ... reduce the effect of uncertainty on objectives. Organizations ... but they improve their capabilities to do this ...
(Date:6/1/2015)... The National Association of Professional Women ... 2015-2016 inductee into the NAPW VIP Professional Woman of ... distinction for leadership in academics. With more than 700,000 ... the nation’s leading networking organization exclusively for professional women. ... distinction,” said NAPW President Star Jones. “She is a ...
(Date:6/1/2015)... 02, 2015 The National Association ... Cornett, DSL, LSSBB (C), First Sergeant A Co., 15BSB ... of the Year Circle. She is recognized with this ... the nation's leading networking organization exclusively for professional women, ... Local Chapters. , “I'm pleased to recognize Sergeant Cornett ...
Breaking Medicine News(10 mins):Health News:Early Single Sport Specialization May Put Youth Athletes at Risk for Overuse Injuries According to Colorado Knee Specialist Robert LaPrade, MD, PhD 2Health News:Early Single Sport Specialization May Put Youth Athletes at Risk for Overuse Injuries According to Colorado Knee Specialist Robert LaPrade, MD, PhD 3Health News:Can Comics Help the United Nations Save the World? 2Health News:Can Comics Help the United Nations Save the World? 3Health News:Specialty Technical Publishers and Radar Launch Online Assessment Program for Evaluation of Risk Management Effectiveness 2Health News:Specialty Technical Publishers and Radar Launch Online Assessment Program for Evaluation of Risk Management Effectiveness 3Health News:Specialty Technical Publishers and Radar Launch Online Assessment Program for Evaluation of Risk Management Effectiveness 4Health News:National Association of Professional Women Inducts Marcia Ditmyer, Vice President of Academy for Academic Leadership, Into its VIP Professional Woman of the Year Circle 2Health News:National Association of Professional Women Inducts Lenita F. Cornett, First Sergeant of the US Military, Into its VIP Professional Woman of the Year Circle 2
... medical information business unit of Cerebrio, LLC, a part of ... International, Inc. (OTC Bulletin Board: MLKNA), a company dedicated to ... the accessibility of physicians and patients to electronic medical records, ... market a suite of unique information products and services. ...
... when tumor is linked to hepatitis B, researchers say ... drug sorafenib increased overall survival in Asian-Pacific patients with ... study that included 226 patients in China, South Korea ... group received 400 milligrams of sorafenib (Nexavar) twice a ...
... But new ,death map, shows that no region is truly ... News) -- Americans worried about being caught up in a ... to avoid the South and the Great Plains states, according ... by University of South Carolina researchers, finds that most deaths ...
... 17 The LCA-Vision Full Value Committee,comprised of Dr. Stephen ... that it has sent a letter to the stockholders of ... Committee,collectively own approximately 11.4% of the Company,s outstanding shares. , ... the letter follows:, A Message from the ...
... The Internet becomes an increasingly important health resource for ... , , NEW YORK, ... not to fill a prescription medication from a doctor ... to pharmaceutical and healthcare market research company Manhattan Research,s ...
... appointments continue to strengthen diagnostics product development business-- , ... HistoRx, Inc., announced today that it has appointed Kathleen ... Diagnostics Marketing and has retained Stephen D. Chubb as a ... Ms. Adams brings to HistoRx 20 years of ...
Cached Medicine News:Health News:Cerebrio, LLC, an Omnicom Group Company, and MedLink International Undertake an Exclusive Development and Marketing Arrangement 2Health News:Drug Helps Asians Battling Liver Cancer 2Health News:Nature's Fury Makes South Most Dangerous Area in U.S. 2Health News:Nature's Fury Makes South Most Dangerous Area in U.S. 3Health News:LCA-Vision's Former Executive Management Team Sends Open Letter to LCA-Vision Stockholders 2Health News:LCA-Vision's Former Executive Management Team Sends Open Letter to LCA-Vision Stockholders 3Health News:LCA-Vision's Former Executive Management Team Sends Open Letter to LCA-Vision Stockholders 4Health News:LCA-Vision's Former Executive Management Team Sends Open Letter to LCA-Vision Stockholders 5Health News:LCA-Vision's Former Executive Management Team Sends Open Letter to LCA-Vision Stockholders 6Health News:LCA-Vision's Former Executive Management Team Sends Open Letter to LCA-Vision Stockholders 7Health News:LCA-Vision's Former Executive Management Team Sends Open Letter to LCA-Vision Stockholders 8Health News:LCA-Vision's Former Executive Management Team Sends Open Letter to LCA-Vision Stockholders 9Health News:LCA-Vision's Former Executive Management Team Sends Open Letter to LCA-Vision Stockholders 10Health News:LCA-Vision's Former Executive Management Team Sends Open Letter to LCA-Vision Stockholders 11Health News:Healthcare Costs Prevented Nearly 40 Million Americans From Filling Their Prescriptions in 2008 2Health News:Healthcare Costs Prevented Nearly 40 Million Americans From Filling Their Prescriptions in 2008 3Health News:HistoRx Names Kate Adams Vice President, Diagnostics Marketing and Retains Steve Chubb as Strategic Advisor 2Health News:HistoRx Names Kate Adams Vice President, Diagnostics Marketing and Retains Steve Chubb as Strategic Advisor 3
(Date:6/1/2015)... , June 1, 2015  Research Solutions, Inc. ... technical and medical (STM) information for life science companies, ... invited to present at the LD Micro Invitational being ... Hotel in Los Angeles . ... present on Wednesday, June 3rd at 9:30 a.m. Pacific ...
(Date:6/1/2015)... 1, 2015 Nevro Corp. (NYSE: NVRO ... innovative evidence-based solutions for the treatment of chronic pain, ... offering of its common stock consisting of 1,475,506 shares ... be sold by certain of its stockholders. In addition, ... to purchase up to an additional 590,202 shares of ...
(Date:6/1/2015)... and MENLO PARK, Calif. ... DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and ... and commercializing proven cancer therapies in new orphan ... its Phase I/II clinical trial of  VAL-083  (dianhydrogalactitol) ... most common and deadly form of human brain ...
Breaking Medicine Technology:Research Solutions to Present at the LD Micro Invitational on June 3, 2015 2Research Solutions to Present at the LD Micro Invitational on June 3, 2015 3Nevro Announces Proposed Public Offering of Common Stock 2Nevro Announces Proposed Public Offering of Common Stock 3DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 2DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 3DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 4DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 5DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 6DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 7DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 8
... of the Criterion precast gel system, allows you ... a single run. Criterion gels are wider and ... mini gel. They accommodate Bio-Rad's 11 cm ReadyStrip ... of separation and speed in 2-D electrophoretic applications. ...
... Mini-Vertical Gel System simplifies the process of separating ... It is able to run four gels at ... maximize utility and throughput, the 120 mini-vertical runs ... (W x L) at one time. The 120 ...
... High-Throughput (HTP) Protein Electrophoresis ... integrated pre-cast gel system ... protein analysis. It consists ... E-Base™ integrated power device, ...
... agarose gel electrophoresis into an automated, high-throughput ... bufferless, pre-cast system is ideal for analyzing ... and more. Fully automated, robot-compatible, and ready ... system makes your high-throughput screening assignments as ...
Medicine Products: